FILINGS
| GLAXF 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2022-05-27 | 6-K | GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA | View Document |
| 2022-05-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-23 | 6-K | FORM 6-K | View Document |
| 2022-05-19 | 6-K | IAIN MACKAY - EXTERNAL APPOINTMENT | View Document |
| 2022-05-17 | 424B3 | 424B3 | View Document |
| 2022-05-17 | 424B3 | 424B3 | View Document |
| 2022-05-16 | 6-K | CHANGE OF NAME TO GSK PLC | View Document |
| 2022-05-13 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-05-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-11 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-05-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-05-09 | 25-NSE | View Document | |
| 2022-05-06 | F-6EF | F-6 | View Document |
| 2022-05-04 | 6-K | RESULT OF AGM | View Document |
| 2022-05-04 | 6-K | DIRECTORATE CHANGE | View Document |
| 2022-05-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-05-02 | 25-NSE | View Document | |
| 2022-04-27 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2022-04-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-19 | 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | DFAN14A | DFAN14A | View Document |
| 2022-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-13 | 6-K | GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-04-01 | 6-K | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES | View Document |
| 2022-03-28 | 6-K | PUBLICATION OF 2022 AGM NOTICE | View Document |
| 2022-03-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-24 | 6-K | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL | View Document |
| 2022-03-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-23 | 6-K | ISSUANCE OF NOTES | View Document |
| 2022-03-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-15 | 6-K | APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| 2022-03-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-08 | 6-K | GSK ANNUAL REPORT 2021 ON FORM 20-F | View Document |
| 2022-03-08 | IRANNOTICE | IRANNOTICE | View Document |
| 2022-03-08 | 20-F | 20-F | View Document |
| 2022-03-04 | 6-K | GSK PUBLISHES ANNUAL REPORT 2021 | View Document |
| 2022-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-03-01 | 6-K | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA | View Document |
| 2022-02-28 | 6-K | FOMR 6-K | View Document |
| 2022-02-28 | 6-K | FORM 6-K | View Document |
| 2022-02-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-24 | 6-K | CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE | View Document |
| 2022-02-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-22 | 6-K | GSK CONSUMER HEALTHCARE TO BE CALLED HALEON | View Document |
| 2022-02-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-18 | 6-K | GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-14 | SC 13G | SC 13G | View Document |
| 2022-02-14 | 6-K | TRANSFER OF TREASURY SHARES | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document |
| 2022-02-10 | SC 13G | SCHEDULE 13G | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO SC 13G | View Document |
| 2022-02-10 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2022-02-10 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2022-02-10 | 6-K | BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS | View Document |
| 2022-02-09 | 6-K | FINAL RESULTS | View Document |
| 2022-02-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-02-07 | SC 13G/A | View Document | |
| 2022-02-07 | 6-K | PUBLICATION OF FULL YEAR 2021 RESULTS | View Document |
| 2022-02-02 | 6-K | GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD | View Document |
| 2022-02-01 | 6-K | FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA | View Document |
| 2022-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-01-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-19 | 6-K | TONY WOOD APPOINTED CSO DESIGNATE, GSK | View Document |
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-18 | 6-K | UPDATE - GSK CONSUMER HEALTHCARE | View Document |
| 2022-01-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-01-11 | 6-K | US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES | View Document |
| 2022-01-04 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2021-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
